Search research articles
Contact Us
Filters
Showing results (51-60 of 61) with videos related to
Page
of 7
Sort By:
Clinical Breast Cancer
|
November 26, 2021
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)
Denise A Yardley, Robyn R Young, Kerin B Adelson, et al.
JAMA
|
April 15, 2023
VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial
Thomas Louie, Yoav Golan, Sahil Khanna, et al.
Clinical and Vaccine Immunology : CVI
|
December 14, 2007
A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax
Larry I Gilderman, James F Lawless, Thomas M Nolen, et al.
Vaccine
|
January 7, 2009
Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age
Scott A Halperin, Bruce Tapiero, Francisco Diaz-Mitoma, et al.
Journal of the American Geriatrics Society
|
October 3, 2007
Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older
Boris Kerzner, Alexander V Murray, Eric Cheng, et al.
The Journal of Infectious Diseases
|
November 1, 2003
Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine
Myron J Levin, Jeffrey G Smith, Robin M Kaufhold, et al.
Vaccine
|
December 14, 2011
Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age
Joost N Vermeulen, Joep M A Lange, Stephen K Tyring, et al.
Vaccine
|
October 20, 2006
Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or =13 years of age
Clemente Diaz, Pietro Dentico, Rocio Gonzalez, et al.
Cell Host & Microbe
|
April 14, 2022
Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers
Melissa Dsouza, Rajita Menon, Emily Crossette, et al.
The Journal of Infectious Diseases
|
May 2, 2013
Safety of zoster vaccine in elderly adults following documented herpes zoster
Vicki A Morrison, Michael N Oxman, Myron J Levin, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 61) with videos related to
Sort By:
Page
of 7
Clinical Breast Cancer
|
November 26, 2021
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)
Denise A Yardley, Robyn R Young, Kerin B Adelson, et al.
JAMA
|
April 15, 2023
VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial
Thomas Louie, Yoav Golan, Sahil Khanna, et al.
Clinical and Vaccine Immunology : CVI
|
December 14, 2007
A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax
Larry I Gilderman, James F Lawless, Thomas M Nolen, et al.
Vaccine
|
January 7, 2009
Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age
Scott A Halperin, Bruce Tapiero, Francisco Diaz-Mitoma, et al.
Journal of the American Geriatrics Society
|
October 3, 2007
Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older
Boris Kerzner, Alexander V Murray, Eric Cheng, et al.
The Journal of Infectious Diseases
|
November 1, 2003
Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine
Myron J Levin, Jeffrey G Smith, Robin M Kaufhold, et al.
Vaccine
|
December 14, 2011
Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age
Joost N Vermeulen, Joep M A Lange, Stephen K Tyring, et al.
Vaccine
|
October 20, 2006
Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or =13 years of age
Clemente Diaz, Pietro Dentico, Rocio Gonzalez, et al.
Cell Host & Microbe
|
April 14, 2022
Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers
Melissa Dsouza, Rajita Menon, Emily Crossette, et al.
The Journal of Infectious Diseases
|
May 2, 2013
Safety of zoster vaccine in elderly adults following documented herpes zoster
Vicki A Morrison, Michael N Oxman, Myron J Levin, et al.
Page
of 7